{"id":69492,"date":"2026-07-07T14:21:21","date_gmt":"2026-07-07T06:21:21","guid":{"rendered":"https:\/\/flcube.com\/?p=69492"},"modified":"2026-07-07T14:21:22","modified_gmt":"2026-07-07T06:21:22","slug":"bristar-immunotech-secures-28m-series-c-to-advance-star-t-platform-and-in-vivo-technology","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69492","title":{"rendered":"BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>BriSTAR Immunotech (Beijing) Co., Ltd.<\/strong> announced the completion of a <strong>Series C financing round exceeding RMB 200 million<\/strong> (approximately <strong>$28 million<\/strong>), led by <strong>Loyal Valley Capital<\/strong> with participation from <strong>Fudan Science and Technology Innovation<\/strong>, to accelerate clinical development and commercialization of its proprietary <strong>STAR-T cell therapy platform<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-financing-details-amp-strategic-allocation\" class=\"wp-block-heading\">Financing Details &amp; Strategic Allocation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Round<\/strong><\/td><td>Series C<\/td><\/tr><tr><td><strong>Amount<\/strong><\/td><td>Over RMB 200 million (~$28 million)<\/td><\/tr><tr><td><strong>Lead Investor<\/strong><\/td><td>Loyal Valley Capital<\/td><\/tr><tr><td><strong>Participating Investor<\/strong><\/td><td>Fudan Science and Technology Innovation<\/td><\/tr><tr><td><strong>Primary Use of Funds<\/strong><\/td><td>Registration clinical development of YTS109 (lead product); In vivo STAR-T platform construction; commercialization system establishment; global IP portfolio expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-company-profile-amp-technology-platforms\" class=\"wp-block-heading\">Company Profile &amp; Technology Platforms<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Founded:<\/strong> 2018<\/li>\n\n\n\n<li><strong>Core Focus:<\/strong> Research, development, and commercialization of <strong>STAR-T technology<\/strong> and <strong>general-purpose site-specific integration technology platform<\/strong><\/li>\n\n\n\n<li><strong>Technology Portfolio:<\/strong><\/li>\n\n\n\n<li><strong>STAR-T Technology Platform<\/strong> \u2013 proprietary T-cell receptor engineering approach<\/li>\n\n\n\n<li><strong>General-Purpose Site-Specific Integration Technology Platform<\/strong> \u2013 enables precise genetic modifications<\/li>\n\n\n\n<li><strong>In Vivo STAR-T Technology Platform<\/strong> \u2013 next-generation approach for direct in vivo T-cell reprogramming<\/li>\n\n\n\n<li><strong>Pipeline:<\/strong> <strong>10+ innovative product candidates<\/strong> spanning hematological tumors, solid tumors, and autoimmune diseases<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-regulatory-milestones-amp-clinical-progress\" class=\"wp-block-heading\">Regulatory Milestones &amp; Clinical Progress<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Achievement<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>Chinese IND Approvals<\/strong><\/td><td>2 granted<\/td><\/tr><tr><td><strong>FDA Designations<\/strong><\/td><td>1 Orphan Drug Designation received<\/td><\/tr><tr><td><strong>Lead Product<\/strong><\/td><td>YTS109 \u2013 general-purpose STAR-T core product advancing toward registration clinical trials<\/td><\/tr><tr><td><strong>Therapeutic Areas<\/strong><\/td><td>Hematological malignancies, solid tumors, autoimmune disorders<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-investment-rationale\" class=\"wp-block-heading\">Strategic Investment Rationale<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Investor<\/th><th>Strategic Rationale<\/th><\/tr><\/thead><tbody><tr><td><strong>Loyal Valley Capital<\/strong><\/td><td>Strong track record in biotechnology investments; expertise in supporting Chinese biotech companies through late-stage clinical development and commercialization<\/td><\/tr><tr><td><strong>Fudan Science and Technology Innovation<\/strong><\/td><td>Academic-commercial bridge leveraging Fudan University&#8217;s research capabilities; focus on cutting-edge cell therapy technologies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The Chinese cell therapy market is projected to reach RMB 15 billion ($2.1 billion) by 2028, with CAR-T therapies currently dominating but significant opportunity remaining for next-generation approaches like STAR-T that may offer improved safety profiles, manufacturing scalability, and cost-effectiveness.<\/p>\n\n\n\n<h2 id=\"h-competitive-landscape-amp-market-opportunity\" class=\"wp-block-heading\">Competitive Landscape &amp; Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Cell Therapy Market:<\/strong> Dominated by autologous CAR-T products with high costs (RMB 1-2 million per treatment) and complex manufacturing logistics<\/li>\n\n\n\n<li><strong>STAR-T Differentiation:<\/strong> General-purpose platform potentially enabling allogeneic (&#8220;off-the-shelf&#8221;) approaches with simplified manufacturing and broader accessibility<\/li>\n\n\n\n<li><strong>In Vivo Technology Potential:<\/strong> Revolutionary approach that could eliminate ex vivo cell processing entirely, dramatically reducing costs and expanding patient access<\/li>\n\n\n\n<li><strong>Global Expansion Strategy:<\/strong> FDA Orphan Drug Designation indicates international regulatory pathway planning alongside domestic development<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding BriSTAR Immunotech&#8217;s financing, clinical development plans, regulatory milestones, and commercial prospects. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, competitive developments, and market dynamics in the rapidly evolving cell therapy landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BriSTAR Immunotech (Beijing) Co., Ltd. announced the completion of a Series C financing round exceeding&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[],"class_list":["post-69492","post","type-post","status-publish","format-standard","hentry","category-company","category-deals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BriSTAR Immunotech (Beijing) Co., Ltd. announced the completion of a Series C financing round exceeding RMB 200 million (approximately $28 million), led by Loyal Valley Capital with participation from Fudan Science and Technology Innovation, to accelerate clinical development and commercialization of its proprietary STAR-T cell therapy platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69492\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology\" \/>\n<meta property=\"og:description\" content=\"BriSTAR Immunotech (Beijing) Co., Ltd. announced the completion of a Series C financing round exceeding RMB 200 million (approximately $28 million), led by Loyal Valley Capital with participation from Fudan Science and Technology Innovation, to accelerate clinical development and commercialization of its proprietary STAR-T cell therapy platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69492\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-07T06:21:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-07T06:21:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69492#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69492\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology\",\"datePublished\":\"2026-07-07T06:21:21+00:00\",\"dateModified\":\"2026-07-07T06:21:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69492\"},\"wordCount\":421,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69492#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69492\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69492\",\"name\":\"BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-07T06:21:21+00:00\",\"dateModified\":\"2026-07-07T06:21:22+00:00\",\"description\":\"BriSTAR Immunotech (Beijing) Co., Ltd. announced the completion of a Series C financing round exceeding RMB 200 million (approximately $28 million), led by Loyal Valley Capital with participation from Fudan Science and Technology Innovation, to accelerate clinical development and commercialization of its proprietary STAR-T cell therapy platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69492#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69492\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69492#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology - Insight, China&#039;s Pharmaceutical Industry","description":"BriSTAR Immunotech (Beijing) Co., Ltd. announced the completion of a Series C financing round exceeding RMB 200 million (approximately $28 million), led by Loyal Valley Capital with participation from Fudan Science and Technology Innovation, to accelerate clinical development and commercialization of its proprietary STAR-T cell therapy platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69492","og_locale":"en_US","og_type":"article","og_title":"BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology","og_description":"BriSTAR Immunotech (Beijing) Co., Ltd. announced the completion of a Series C financing round exceeding RMB 200 million (approximately $28 million), led by Loyal Valley Capital with participation from Fudan Science and Technology Innovation, to accelerate clinical development and commercialization of its proprietary STAR-T cell therapy platform.","og_url":"https:\/\/flcube.com\/?p=69492","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-07T06:21:21+00:00","article_modified_time":"2026-07-07T06:21:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69492#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69492"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology","datePublished":"2026-07-07T06:21:21+00:00","dateModified":"2026-07-07T06:21:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69492"},"wordCount":421,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69492#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69492","url":"https:\/\/flcube.com\/?p=69492","name":"BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-07T06:21:21+00:00","dateModified":"2026-07-07T06:21:22+00:00","description":"BriSTAR Immunotech (Beijing) Co., Ltd. announced the completion of a Series C financing round exceeding RMB 200 million (approximately $28 million), led by Loyal Valley Capital with participation from Fudan Science and Technology Innovation, to accelerate clinical development and commercialization of its proprietary STAR-T cell therapy platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69492#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69492"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69492#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69492","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69492"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69492\/revisions"}],"predecessor-version":[{"id":69493,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69492\/revisions\/69493"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69492"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69492"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}